Jul 14, 2025, 15:56

AstraZeneca: Externally Sponsored Scientific Research (ESR) – Cardiovascular, Metabolic & Renal Focus

AstraZeneca’s ESR programme supports independent observational and real-world evidence studies exploring the renal and heart-failure benefits of SGLT2 inhibition (dapagliflozin), potassium-binder strategies (sodium zirconium cyclosilicate), antisense oligonucleotide approaches in transthyretin amyloidosis, and aldosterone synthase inhibition. These grants are intended for projects completed within a two-year timeframe that generate high-quality data to inform patient management and health-economic models.

Eligibility Criteria:

External investigators at academic, clinical, or research institutions.
Proposals must leverage AstraZeneca compounds listed below or generate unbranded real-world data.
Studies must align with local regulatory standards and ethics codes.

Funding Details:

Support Type: Drug supply, data-analysis resources, assay costs, and limited operational budgets.
Compounds & Interests:
- Dapagliflozin (Forxiga/Farxiga): RWE on disease burden, treatment patterns, risk prediction, and management in kidney disease or heart failure.
- Sodium Zirconium Cyclosilicate (Lokelma): Unbranded data generation on hyperkalaemia prevalence, treatment patterns, GDMT optimization; SZC-specific analyses of long-term use and in-hospital care pathways.
- Eplontersen (Wainua/Wainzua): Biomarker and AI/ML-based early detection, disease monitoring tools, and PRO linkage in ATTR amyloidosis.
- Baxdrostat: Mechanistic studies contrasting aldosterone synthase inhibition versus MR antagonism, and non-MR effects on inflammation and fibrosis.

Deadline:

Continuous submission via the ESR portal; funding decisions communicated within 45 days of complete proposal.

Where to Go for Further Information:

Register and submit at the AstraZeneca Open Innovation ESR portal. Contact your local medical representative for strategic alignment prior to submission.

aldosterone synthase AstraZeneca ATTR Amyloidosis cancer cardiology externally sponsored research heart failure hyperkalaemia interventional clinical trials Nephrology non-clinical research OncoDaily Oncology open innovation pharmacodynamics Pharmacokinetics real-world evidence renal disease SGLT2 transparency

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter